The distinction that matters
Melanotan I and Melanotan II are frequently discussed together and are not interchangeable. Melanotan I is a selective melanocortin-1 receptor agonist; Melanotan II acts non-selectively across melanocortin receptors, which is why it produces effects — including priapism and nausea — that Melanotan I largely does not.
More importantly, Melanotan I has a legitimate pharmaceutical descendant. Afamelanotide, marketed as Scenesse, is an approved medicine.
What afamelanotide is approved for
Afamelanotide (Scenesse) is approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare inherited disorder in which sunlight exposure causes severe burning pain.
It is administered as a controlled-release implant inserted under the skin by a trained healthcare professional, in specialist centres, with ongoing monitoring including skin surveillance.
The injectable Melanotan I sold online is not this product. It is unlicensed and cannot be lawfully supplied for human use.
EPP is a genuinely serious condition. People with it cannot tolerate sunlight without severe pain, and before afamelanotide there was very little to offer them. The approval reflects a real benefit in a population with a real and disabling problem.
An approved implant for a rare inherited disease is not evidence that an unregulated injection for a cosmetic tan is safe.
Why the differences are not pedantic
- Different product. A controlled-release implant delivers a defined amount over a defined period. An injectable vial of unverified content does not.
- Different population. EPP patients have a specific pathology and a specific unmet need. The risk-benefit calculation that justified approval was made for them.
- Different supervision. The licensed product is inserted by trained staff in specialist centres, with skin monitoring built into the treatment pathway. That monitoring exists because stimulating melanocytes warrants surveillance.
- Different manufacturing. Scenesse is a manufactured pharmaceutical. Online Melanotan I is not.
The melanocyte question applies here too
Any melanocortin-1 agonist stimulates melanocytes. This is why skin surveillance is part of the licensed treatment pathway for afamelanotide, rather than an optional extra.
Someone using unregulated Melanotan I for cosmetic tanning gets the melanocyte stimulation without the surveillance. If moles change in size, shape or colour, see a GP.
The MHRA position on the grey-market version
MHRA warnings on unlicensed tanning products have named Melanotan I alongside Melanotan II. The agency has stated that no such product is approved for use in the UK, that they carry health risks as unlicensed medicines, and has acted against websites supplying them. Adverse reaction reports received by the agency cover melanotan products generally.
Where this leaves you
If you have erythropoietic protoporphyria, there is an approved treatment and it should be accessed through specialist services. If you want a cosmetic tan, the existence of that approval tells you nothing useful about the safety of an unregulated vial, and topical self-tanning products achieve the cosmetic goal without stimulating melanocytes at all.